Chardan Healthcare Acquisition Corp (CHAC.UN1)

Sector:
FINANCE
Industry:
GENERAL FINANCE
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Jonathan Eitan Solomon
Employees:
17 STATE STREET, 16TH FLOOR, NEW YORK, NY 10004
646-465-9000

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome.

Data derived from most recent annual or quarterly report
Market Cap 0 Shares Outstanding0 Avg 30-day Volume 3.636 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0.38
Price to Revenue0.0 Debt to Equity0.5489 EBITDA-32.912 Million
Price to Book Value1.4363 Operating Margin0.0 Enterprise Value33.696 Million
Current Ratio EPS Growth0 Quick Ratio
1 Yr BETA -0.2372 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-19.3536 Altman Z-Score Free Cash Flow to Firm -29.725 Million
View SEC Filings from CHAC.UN1 instead.

View recent insider trading info

Funds Holding CHAC.UN1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CHAC.UN1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-27:
    Item 8.01: Other Events
  • 8-K: filed on 2022-06-14:
    Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-24:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-18:
    Item 8.01: Other Events
  • 8-K: filed on 2021-08-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-26:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SEKHRI PAUL J

    • Director
    0 2020-10-02 0

    MOSES ALAN CHARLES

    • Director
    0 2020-10-02 0

    PROPPER KERRY

    MOUNTAIN WOOD LLC

    • 10% Owner
    No longer subject to file 2020-07-13 0

    AMUSA GBOLAHAN

    • Director
    237,871 2020-07-13 0

    GROSSMAN JONAS

    • Director
    335,217 2020-06-18 0

    CHIMOVITS EREZ

    • Director
    • 10% Owner
    2,313,489 2020-03-25 0

    SULLIVAN LYNNE MARIE

    • Director
    0 2020-03-25 0

    GREIG RUSSELL

    • Director
    0 2020-03-25 0

    ORON ASSAF CHIEF BUSINESS OFFICER

    • Officer
    0 2020-03-25 0

    PUTTAGUNTA SAILAJA CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2020-03-25 0

    SOLOMON JONATHAN EITAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    0 2020-03-25 0

    BRESKI YARON

    • Director
    0 2020-03-25 0

    WOLFSON MARINA PRINCIPAL FINANCIAL OFFICER

    • Officer
    0 2020-03-25 0

    BEN-OR URI

    • Director
    0 2019-10-30 0

    TAKEDA PHARMACEUTICAL CO LTD

    TAKEDA VENTURES, INC.

    • 10% Owner
    2,470,935 2019-10-28 0

    ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP

    ORBIMED ISRAEL GP LTD.

    • 10% Owner
    2,290,490 2019-10-28 0

    GOLEMBO MYRIAM VICE PRESIDENT OF DEVELOPMENT

    • Officer
    0 2019-10-28 0

    GAHALI-SASS INBAR VP OF PLATFORM RESEARCH&DEVEL.

    • Officer
    0 2019-10-28 0

    WOODMAN ROBBIE

    • Director
    0 2019-10-28 0

    BASSAN MERAV CHIEF DEVELOPMENT OFFICER

    • Officer
    0 2019-10-28 0

    MMCAP INTERNATIONAL INC. SPC

    • 10% Owner
    1,700,000 2018-12-18 0

    RICE YEHUDA MICHAEL

    • Director
    7,500 2018-12-13 0

    GIROUX RICHARD

    • Director
    7,500 2018-12-13 0

    CHARDAN INVESTMENTS, LLC

    • 10% Owner
    1,970,000 2018-12-13 0

    KAUFMAN GEORGE CFO & HOS & DIRECTOR

    • Officer
    • Director
    0 2018-12-13 0

    KUSSELUK ERIC

    • Director
    7,500 2018-12-13 0

    ROSSEN MATTHEW

    • Director
    7,500 2018-12-13 0

    GNEDY ELLIOT

    • Director
    7,500 2018-12-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments